Extended-schedule dose-dense temozolomide in refractory gliomas

Area of Science:

• Neuro-Oncology
• Clinical Pharmacology
• Malignant Glioma Treatment

Background:

• Malignant gliomas are aggressive brain tumors with limited treatment options.
• Temozolomide is a standard chemotherapy agent, but resistance often develops.
• Identifying effective salvage therapies for temozolomide-refractory glioma is crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of an extended, dose-dense temozolomide regimen.
• To assess treatment activity in adult patients with temozolomide-refractory WHO grade III or IV malignant glioma.

Main Methods:

• A multicenter phase II study involving 47 adult patients with refractory malignant glioma.
• Patients received temozolomide (85 mg/m²/day) for 21 consecutive days every 28-day cycle.
• Treatment continued until disease progression or unacceptable toxicity.

Main Results:

• Partial response in 6.4% of patients; stable disease in 31.9% (2 patients >6 months).
• Median time to progression was 2 months; median overall survival was 5.1 months.
• Common toxicities included lymphopenia (83%), thrombocytopenia, and leukopenia, with manageable severity.

Conclusions:

• The extended, dose-dense temozolomide schedule has modest activity in patients refractory to prior temozolomide treatment.
• This regimen is associated with manageable hematologic toxicities, including lymphopenia.
• This approach may offer a therapeutic option for patients with progressive malignant glioma after standard temozolomide therapy.